Recent Analysts’ Ratings Updates for Bio-Rad Laboratories (BIO)

Bio-Rad Laboratories (NYSE: BIO) recently received a number of ratings updates from brokerages and research firms:

• 8/11/2026 – Bio-Rad Laboratories was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/5/2026 – Bio-Rad Laboratories had its price target raised by Citigroup Inc. from $300.00 to $330.00. They now have a “hold” rating on the stock.
• 8/5/2026 – Bio-Rad Laboratories had its price target raised by Royal Bank Of Canada from $320.00 to $370.00. They now have an “outperform” rating on the stock.
• 8/5/2026 – Bio-Rad Laboratories had its price target raised by Wells Fargo & Company from $310.00 to $330.00. They now have an “equal weight” rating on the stock.
• 8/3/2026 – Bio-Rad Laboratories had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Bio-Rad Laboratories was downgraded by Zacks Research from “hold” to “strong sell”.

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.